Evidence map›Paper›PMID 34653226›Full record

ArticlePLoS pathogens2021

Hantaviruses use the endogenous host factor P58IPK to combat the PKR antiviral response.

Zekun Wang, Songyang Ren, Qiming Li, Austin D Royster, Lei Lin, Sichen Liu, Safder S Ganaie, Jianming Qiu, Sheema Mir, Mohammad A Mir

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Viral evasion of PKR restriction by reprogramming cellular stress granules.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Zekun WangJoint National Laboratory for Antibody Drug Engineering, School of Basic Medical Sciences, Henan University, Kaifeng, China.
Songyang RenWestern University of Health Sciences, Pomona, California, United States of America.
Qiming LiJoint National Laboratory for Antibody Drug Engineering, School of Basic Medical Sciences, Henan University, Kaifeng, China.
Austin D RoysterWestern University of Health Sciences, Pomona, California, United States of America.ORCID 0000-0001-8578-9888
Lei LinJoint National Laboratory for Antibody Drug Engineering, School of Basic Medical Sciences, Henan University, Kaifeng, China.
Sichen LiuJoint National Laboratory for Antibody Drug Engineering, School of Basic Medical Sciences, Henan University, Kaifeng, China.
Safder S GanaieDepartment of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.ORCID 0000-0002-9014-6577
Jianming QiuDepartment of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, Kansas, United States of America.ORCID 0000-0001-9850-1695
Sheema MirWestern University of Health Sciences, Pomona, California, United States of America.
Mohammad A MirWestern University of Health Sciences, Pomona, California, United States of America.ORCID 0000-0003-3457-0733
Henan University · CNWestern University of Health Sciences · USUniversity of Kansas Medical Center · US

Funding

Viral and Host Determinants of Parvovirus ReplicationR01AI150877 · NIAID · UNIVERSITY OF KANSAS MEDICAL CENTER · PI QIU, JIANMING · 2020 to 2024
$2.4M
Preferential translation of host cell factors by hantavirus nucleocapsid proteinR15AI126395 · NIAID · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI MIR, MOHAMMAD A · 2017 to 2017
$429k
NIAID NIH HHS R01 AI150877NIAID NIH HHS R15 AI126395
6 · The paper itself

Abstract

Hantavirus nucleocapsid protein (NP) inhibits protein kinase R (PKR) dimerization by an unknown mechanism to counteract its antiviral responses during virus infection. Here we demonstrate that NP exploits an endogenous PKR inhibitor P58IPK to inhibit PKR. The activity of P58IPK is normally restricted in cells by the formation of an inactive complex with its negative regulator Hsp40. On the other hand, PKR remains associated with the 40S ribosomal subunit, a unique strategic location that facilitates its free access to the downstream target eIF2α. Although both NP and Hsp40 bind to P58IPK, the binding affinity of NP is much stronger compared to Hsp40. P58IPK harbors an NP binding site, spanning to N-terminal TPR subdomains I and II. The Hsp40 binding site on P58IPK was mapped to the TPR subdomain II. The high affinity binding of NP to P58IPK and the overlap between NP and Hsp40 binding sites releases the P58IPK from its negative regulator by competitive inhibition. The NP-P58IPK complex is selectively recruited to the 40S ribosomal subunit by direct interaction between NP and the ribosomal protein S19 (RPS19), a structural component of the 40S ribosomal subunit. NP has distinct binding sites for P58IPK and RPS19, enabling it to serve as bridge between P58IPK and the 40S ribosomal subunit. NP mutants deficient in binding to either P58IPK or RPS19 fail to inhibit PKR, demonstrating that selective engagement of P58IPK to the 40S ribosomal subunit is required for PKR inhibition. Cells deficient in P58IPK mount a rapid PKR antiviral response and establish an antiviral state, observed by global translational shutdown and rapid decline in viral load. These studies reveal a novel viral strategy in which NP releases P58IPK from its negative regulator and selectively engages it on the 40S ribosomal subunit to promptly combat the PKR antiviral responses.

Indexed as

eIF-2 KinaseHantavirus InfectionsHEK293 CellsHeLa CellsHost Microbial InteractionsHumansNucleocapsid ProteinsOrthohantavirusEIF2AK2 protein, humaneIF-2 KinaseNucleocapsid Proteins

Identifiers

PMID34653226
PMCPMC8550428
OpenAlexW3205391365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.